US equities
|
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
INTC
$119.13
▼-0.17%
MU
$1,074.89
▲+0.00%
NVDA
$233.95
▲+0.00%
SNDK
$1,719.99
▲+0.00%
SPCX
$158.96
▲+0.00%
TSLA
$370.59
▲+0.00%
SDEV
$7.48
▲+0.00%
AMD
$633.91
▲+0.00%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Articles published by Sema4
Sema4|GeneDx to Participate in the 41st Annual J.P. Morgan Healthcare Conference
December 30, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
New Research from Sema4|GeneDx Highlights the Importance of Rapid Exome Sequencing for Diagnosing Mitochondrial Diseases in the NICU
December 05, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4 Reports Third Quarter 2022 Financial Results and New Strategic Direction
November 14, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4 to Report Third Quarter 2022 Financial Results on Monday, November 14th, 2022
November 04, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4|GeneDx Commends New Evidence-Based Guidelines from the National Society of Genetic Counselors Recommending Exome Sequencing as a First-Tier Genetic Test for Unexplained Epilepsies
October 31, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4|GeneDx Announces Results from Phase 1 of SeqFirst Study, Demonstrating Broad Utility of Rapid Whole Genome Sequencing for Critically Ill Newborns
October 27, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4|GeneDx collaborates on new research demonstrating genome and exome sequencing deliver more diagnostic certainty than multi-gene panels
October 26, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Study Demonstrates the Utility of Exome Sequencing for Diagnosing Autism Spectrum Disorders
October 13, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4|GeneDx To Provide Whole Genome Sequencing and Interpretation Services for Landmark Genomic Newborn Screening Study
October 05, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Sema4 to Report Second Quarter 2022 Financial Results on Monday, August 15, 2022
July 26, 2022
From
Sema4
Via
GlobeNewswire
Tickers
SMFR
SMFRW
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
July 07, 2021
From
Sema4
Via
Business Wire
Sema4 Appoints Andrew Kasarskis, Health Data Expert and Precision Medicine Scientist, as Chief Data Officer
June 17, 2021
From
Sema4
Via
Business Wire
Sema4 and CM Life Sciences Announce the Filing of Amended Preliminary Proxy Statement
June 10, 2021
From
Sema4
Via
Business Wire
AdventHealth and Sema4 Launch a Data-driven Precision Medicine Program to Optimize Patient Care and Outcomes
May 25, 2021
From
Sema4
Via
Business Wire
Sema4 to Participate in Upcoming Investor Conferences
May 24, 2021
From
Sema4
Via
Business Wire
Sema4 and CM Life Sciences Announce the Filing of the Schedule-14A Proxy Statement in Connection with the Proposed Merger
May 06, 2021
From
Sema4
Via
Business Wire
NorthShore and Sema4 Launch System-Wide Genomics Program to Improve Primary and Specialty Care with Data-Driven Insights
April 19, 2021
From
Sema4
Via
Business Wire
